Cargando…
Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)
OBJECTIVE: This study aimed to assess the minimal clinically important differences (MCIDs) for the modified Rodnan skin score (mRSS) using combined data from the Scleroderma Lung Studies (I and II). METHODS: MCID estimates for the mRSS at 12 months were calculated using three anchors: change in scor...
Autores principales: | Khanna, Dinesh, Clements, Philip J., Volkmann, Elizabeth R., Wilhalme, Holly, Tseng, Chi-hong, Furst, Daniel E., Roth, Michael D., Distler, Oliver, Tashkin, Donald P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335851/ https://www.ncbi.nlm.nih.gov/pubmed/30651141 http://dx.doi.org/10.1186/s13075-019-1809-y |
Ejemplares similares
-
Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma
por: Low, Andrea H. L., et al.
Publicado: (2019) -
Racial Disparities in Systemic Sclerosis: Short‐ and Long‐Term Outcomes Among African American Participants of SLS I and II
por: Volkmann, Elizabeth R., et al.
Publicado: (2020) -
SLS
por: Association du personnel
Publicado: (2007) -
Data Storage for the SLS
por: Sekolec, L, et al.
Publicado: (1999) -
Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial
por: Tashkin, Donald P, et al.
Publicado: (2016)